Novartis’s Entresto Receives US FDA’s Approval for Chronic Heart Failure

February 17, 2021 Auto Bot approval, Chronic Heart Failure, FDA, Novartis, receives, regulatory 0

Shots:

  • The approval is based on P-III PARAGON-HF study involves assessing of Entresto (sacubitril/valsartan) in the treatment of patients with preserved ejection fraction HFpEF
  • The expanded indication enables potential treatment of adults with left ventricular ejection fraction (LVEF) below normal, benefits are most clearly evident
  • Entresto is the 1st and only therapy approved in the US to treat patients diagnosed with guideline defined heart failure to include both those with HFrEF and many with HFpEF

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Penn Medicine

The post Novartis’s Entresto Receives US FDA’s Approval for Chronic Heart Failure first appeared on PharmaShots.